In this roundtable, representatives from Sharsheret, the Cancer Support Community, the Young Survival Coalition, and Living Beyond Breast Cancer discuss the impact of metastatic breast cancer.
In this roundtable, representatives from Sharsheret, the Cancer Support Community, the Young Survival Coalition, and Living Beyond Breast Cancer discuss the impact of metastatic breast cancer. The video is part of the Advocacy in Action: Young Women Living with Metastatic Breast Cancer initiative.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Real-World Data Confirm Ide-cel Safety and Efficacy for Patients With Multiple Myeloma
February 2nd 2023Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer
2 Clarke Drive
Cranbury, NJ 08512